Jounce Therapeutics Reports Third Quarter 2020 Financial Results
-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811- -Initiated the Phase 2 SELECT biomarker selection trial of vopratelimab in combination with JTX-4014- - …